PPBT on Nasdaq
Kitov Pharma
Clinical stage biopharmaceutical company.1
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with Galena Biopharma, Shattuck Labs, Inc. or 60 DEGREES PHARMACEUTICALS, INC., or pick any stock.
- TickerPPBT on Nasdaq1
- Industrybiopharmaceutical1
- Headquartersתל אביב-יפו1
- Legal formpublic company1
- Listed onTel Aviv Stock Exchange (KTOV), Nasdaq (KTOV)1
- Incorporated inIsrael4
- Business address4 Oppenheimer Street, Science Park, Rehovot, L3 76701044
- Filer categoryNon-accelerated filer4
See how the biggest companies compare on our leaderboards
The Company is headquartered in Rehovot, Israel and our telephone number is +972-3-933-3121. Our website address is www.purple-biotech.com.5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2020
-1261.2%Operating margin6
2870.1%Net margin7
0.0%Revenue growth, 20208
36.0%Return on equity9
$1.5MFree cash flow7
Where the money goes
Where each dollar of revenue went, fiscal 2020
- Selling, general and admin17¢$6.0M
- Profit83¢$28.7M
Where each dollar of operating cash went, fiscal 2020
- Capital spending9¢$156.0K
- Kept or used elsewhere91¢$1.5M
Financial statements
No quarterly figures reported.
Every line of the income statement as filed: the last 3 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Research and development expenses | $3.7M | $7.6M | $17.0M |
| General and administrative expenses | $3.2M | $3.2M | $5.2M |
| Impairment loss | $20.5M | $202.0K | |
| Operating loss | $27.5M | $11.0M | $22.3M |
| Change in fair value of warrants | -$1.5M | -$3.3M | -$3.5M |
| Finance expenses | $982.0K | $483.0K | $2.2M |
| Finance income | -$424.0K | -$868.0K | -$992.0K |
| Finance income, net | -$966.0K | -$3.7M | -$2.3M |
| Loss for the year | $26.5M | $7.3M | $20.0M |
| Loss (profit) from cash flow hedges | $19.0K | -$25.0K | |
| Owners of the Company | $26.4M | $7.2M | $19.9M |
| Non-controlling interests | $106.0K | $39.0K | $97.0K |
| Owners of the Company | $26.4M | $7.3M | $19.9M |
| Non-controlling interests | $106.0K | $39.0K | $97.0K |
| Total comprehensive loss for the year | $26.5M | $7.3M | $20.0M |
| Basic loss per Share USD (in Dollars per share) | $0.03 | ||
| Diluted loss per Share USD (in Dollars per share) | $0.03 | ||
| Number of ADSs used in calculation (in Shares) | 480.1K shares | ||
| Number of Shares used in calculation (in Shares) | 960.1M shares |
No quarter-by-quarter statement was filed.
No quarterly figures reported.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $8.7M | $7.4M | $14.5M | $15.0M |
| Short term deposits | $857.0K | $848.0K | ||
| Other investments | $275.0K | |||
| Other current assets | $292.0K | $384.0K | ||
| Total current assets | $9.9M | $8.9M | ||
| Right to use assets | $222.0K | $164.0K | ||
| Fixed assets, net | $124.0K | $124.0K | ||
| Intangible assets | $7.4M | $27.8M | ||
| Total non - current assets | $7.7M | $28.1M | ||
| Total assets | $17.6M | $37.0M | ||
| Current maturity of lease liabilities | $244.0K | $183.0K | ||
| Trade payable | $2.1M | $1.5M | ||
| Warrants | $4.1M | $1.1M | ||
| Other payables | $1.4M | $1.2M | ||
| Total current liabilities | $7.8M | $4.0M | ||
| Post-employment benefit liabilities | $160.0K | $140.0K | ||
| Total non - current liabilities | $160.0K | $140.0K | ||
| Share premium | $152.5M | $147.6M | ||
| Receipts on account of warrants | $21.1M | $21.1M | ||
| Capital reserve for share-based payments | $7.3M | $8.9M | ||
| Capital reserve from transactions with related parties | $761.0K | $761.0K | ||
| Capital reserve from transactions with non- controlling interest | -$859.0K | -$859.0K | ||
| Accumulated loss | -$171.1M | -$144.7M | ||
| Equity attributable to owners of the Company | $9.7M | $32.9M | ||
| Non-controlling interests | -$55.0K | $51.0K | ||
| Total equity | $9.7M | $32.9M | $34.3M | $47.1M |
| Total liabilities and equity | $17.6M | $37.0M |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $8.7M | $7.4M | $14.5M | $15.0M |
| Short term deposits | $857.0K | $848.0K | ||
| Other investments | $275.0K | |||
| Other current assets | $292.0K | $384.0K | ||
| Total current assets | $9.9M | $8.9M | ||
| Right to use assets | $222.0K | $164.0K | ||
| Fixed assets, net | $124.0K | $124.0K | ||
| Intangible assets | $7.4M | $27.8M | ||
| Total non - current assets | $7.7M | $28.1M | ||
| Total assets | $17.6M | $37.0M | ||
| Current maturity of lease liabilities | $244.0K | $183.0K | ||
| Trade payable | $2.1M | $1.5M | ||
| Warrants | $4.1M | $1.1M | ||
| Other payables | $1.4M | $1.2M | ||
| Total current liabilities | $7.8M | $4.0M | ||
| Post-employment benefit liabilities | $160.0K | $140.0K | ||
| Total non - current liabilities | $160.0K | $140.0K | ||
| Share premium | $152.5M | $147.6M | ||
| Receipts on account of warrants | $21.1M | $21.1M | ||
| Capital reserve for share-based payments | $7.3M | $8.9M | ||
| Capital reserve from transactions with related parties | $761.0K | $761.0K | ||
| Capital reserve from transactions with non- controlling interest | -$859.0K | -$859.0K | ||
| Accumulated loss | -$171.1M | -$144.7M | ||
| Equity attributable to owners of the Company | $9.7M | $32.9M | ||
| Non-controlling interests | -$55.0K | $51.0K | ||
| Total equity | $9.7M | $32.9M | $34.3M | $47.1M |
| Total liabilities and equity | $17.6M | $37.0M |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Loss for the year | -$26.5M | -$7.3M | -$20.0M |
| Depreciation | $203.0K | $186.0K | $197.0K |
| Impairment loss | $20.5M | $202.0K | |
| Finance income, net | -$966.0K | -$3.7M | -$2.3M |
| Share-based payments | $309.0K | $582.0K | $1.9M |
| Total adjustments | -$6.5M | -$10.0M | -$20.2M |
| Changes in other current assets | $153.0K | $96.0K | $178.0K |
| Changes in trade payables | $450.0K | -$2.1M | $1.3M |
| Changes in other payables | $205.0K | -$2.4M | -$1.1M |
| Changes in post-employment benefit liabilities | -$162.0K | ||
| Changes in assets and liabilities, total | $808.0K | -$4.3M | $274.0K |
| Net cash used in operating activities | -$5.7M | -$14.4M | -$19.9M |
| Acquisition of subsidiary, net of cash acquired (see Note 4C) | -$3.5M | ||
| Proceed from other investments | $458.0K | $187.0K | $875.0K |
| Decrease (increase) in short term deposits | -$9.0K | $2.0K | $15.8M |
| Interest received | $186.0K | $320.0K | $755.0K |
| Acquisition of fixed assets | -$3.0K | -$3.0K | |
| Net cash provided by investing activities | $632.0K | $509.0K | $13.9M |
| Proceeds from issuance of ADSs | $3.2M | $5.8M | $1.6M |
| ADS issuance expenses paid | -$312.0K | -$556.0K | -$229.0K |
| Proceeds from issuance of warrants and prefunded warrants | $4.2M | $5.0M | |
| Proceeds from warrant inducement transaction | $2.0M | ||
| Warrants issuance expenses paid | -$508.0K | -$280.0K | -$661.0K |
| Repayment of lease liability | -$217.0K | -$183.0K | -$168.0K |
| Interest paid | -$23.0K | -$44.0K | -$56.0K |
| Net cash provided by financing activities | $6.3M | $6.8M | $5.4M |
| Net increase (decrease) in cash and cash equivalents | $1.3M | -$7.1M | -$595.0K |
| Effect of translation adjustments on cash and cash equivalents | $7.0K | -$4.0K | $54.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led Kitov Pharma, and when. Pick a name to see everywhere that person has worked.
Chief executive
197019801990200020102020
Board members and other officers (5)
- Head of Clinical & Reg AffairsMichael Schickler Mar 30, 2026 to now12
- Board memberRobert E. Gagnon Mar 18, 2026 to now13
- Board memberIdo Agmon Apr 6, 2026 to now14
- Board memberSuzana Zilberberg Apr 7, 2026 to now15
- Board memberSimcha Rock Apr 17, 2026 to now16
Named in SEC Form D filings
People the company listed in its private-offering notices.
- Vice President of Research and DevelopmentHadas Reuveni named Oct 31, 2023 to Jul 15, 202417
- Vice President of OperationsIdo Morpurgo named Oct 31, 2023 to Jul 15, 202417
- Chief Financial OfficerLior Fhima named Oct 31, 2023 to Jul 15, 202417
- Chief Business OfficerFabien Sebille named Oct 31, 202318
- Chairman of the Board of DirectorsEric Rowinsky named Oct 31, 2023 to Jul 15, 202417
- DirectorIsaac Israel named Oct 31, 2023 to Jul 15, 202417
- DirectorOri Hershkovitz named Oct 31, 2023 to Jul 15, 202417
- DirectorYael Margolin named Jul 15, 202417
Former names
Timeline
Filings
217 filings to the SEC since October 2021: 5 annual reports, 8 insider forms, 10 large holders, 2 private raises, 192 other. The latest 20:
- Oct 5, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Sep 9, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Sep 2, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 10, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Aug 7, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jul 29, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jun 23, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jun 11, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- May 20, 2026F-3 REGISTRATION STATEMENT EDGAR
- May 15, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- May 13, 2026SCHEDULE 13G/A EDGAR
- Apr 27, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Apr 23, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Apr 17, 20263 EDGAR
- Apr 7, 20263 EDGAR
- Apr 6, 20263 EDGAR
- Mar 31, 20263 EDGAR
- Mar 30, 20263/A EDGAR
- Mar 30, 20263 EDGAR
The 217 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- SUSQUEHANNA SECURITIES, LLCSCHEDULE 13G/A, 2 filings Feb 13, 2026 to Aug 14, 202619
- INTRACOASTAL CAPITAL, LLCSCHEDULE 13G/A, 3 filings Sep 10, 2025 to May 13, 202620
- Lincoln Alternative Strategies LLCSCHEDULE 13G, 1 filing Sep 9, 202521
- Orca Capital AGSCHEDULE 13G/A, 2 filings Sep 9, 202522
- ARMISTICE CAPITAL, LLCSC 13G/A, 2 filings Feb 14, 2024 to Nov 14, 202423
Money raised
Private offerings the company reported to the SEC on Form D.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| SmartHarvest Portfolios, LLC | 28,468 | $47.8K | 0.0% | +10,341 |
| Citadel Advisors LLC | 13,166 | $22.1K | 0.0% | New |
| Susquehanna International Group, Llp | 12,847 | $21.6K | 0.0% | −40,556 |
| Independent Advisor Alliance | 11,901 | $20.0K | 0.0% | New |
| Arax Advisory Partners | 1,453 | $2.4K | 0.0% | New |
| Rhumbline Advisers | 856 | $1.4K | 0.0% | +146 |
| UBS Group AG | 751 | $1.3K | 0.0% | +652 |
| Morgan Stanley | 197 | $331 | 0.0% | −381 |
| Hrt Financial LP | 14,640 | $24 | 0.0% | New |
| Northwestern Mutual Wealth Management Co | 8 | $13 | 0.0% | No change |
| IFG Advisory, LLC | 7 | $12 | 0.0% | New |
| SBI Securities Co., Ltd. | 3 | $5 | 0.0% | −28 |
| Royal Bank Of Canada | 128 | $0 | 0.0% | +118 |
13F reports cover disclosed long positions in U.S. stocks only.
Links
- WikidataQ96482278
- SEC EDGARCIK 1614744
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataKitov Pharma on Wikidata
- 2SEC EDGARKitov Pharma filings on SEC EDGAR
- 3SEC EDGARKitov Pharma 10-K for fiscal 2025
- 4SEC EDGARKitov Pharma filings on SEC EDGAR
- 5
- 6SEC EDGARKitov Pharma 10-K for fiscal 2020
- 7SEC EDGARKitov Pharma 10-K for fiscal 2020
- 8SEC EDGARKitov Pharma 10-K for fiscal 2020
- 9SEC EDGARKitov Pharma 10-K for fiscal 2020
- 10SEC EDGARKitov Pharma 10-K for fiscal 2018
- 11SEC EDGARGil Efron, Chief executive officer
- 12
- 13SEC EDGARRobert E. Gagnon, Board member
- 14SEC EDGARIdo Agmon, Board member
- 15SEC EDGARSuzana Zilberberg, Board member
- 16SEC EDGARSimcha Rock, Board member
- 17
- 18
- 19
- 20
- 21
- 22
- 23